The Use of Etanercept (Enbrel) as Sole Treatment for Grade I Acute Graft Versus Host Disease
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine with statistical certainty that treatment with etanercept alone for Grade I (stage 1-2 skin only) acute GVHD will reduce the percentage of patients who progress within 28 days of initiation of etanercept treatment, from 58% to 38%.
Sung Choi, MD
The University of Michigan Comprehensive Cancer Center
United States: Institutional Review Board
|University of Michigan||Ann Arbor, Michigan 48109-0624|